N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
Asthma EQ-5D | |||||||
York A1 tariff | 255 | 0.83 | 0.84 | 0.01 | 0.00 | 0.02 | 0.23 |
VAS | 248 | 73.77 | 74.33 | 0.56 | −1.09 | 2.21 | 0.50 |
Asthma MINI-AQLQ | |||||||
Symptoms | 252 | 5.29 | 5.29 | 0.00 | −0.12 | 0.12 | 0.99 |
Activity Limitations | 240 | 6.08 | 5.92 | −0.15 | −0.26 | −0.05 | 0.00 |
Emotional Functioning | 253 | 5.37 | 5.28 | −0.09 | −0.23 | 0.05 | 0.21 |
Environmental Stimuli | 255 | 5.30 | 5.24 | −0.05 | −0.17 | 0.07 | 0.38 |
Total QOL | 226 | 5.60 | 5.52 | −0.07 | −0.17 | 0.02 | 0.13 |
N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
COPD EQ-5D | |||||||
York A1 tariff | 177 | 0.67 | 0.67 | 0.00 | −0.02 | 0.01 | 0.77 |
VAS | 173 | 62.29 | 62.14 | −0.14 | −2.94 | 2.66 | 0.92 |
COPD CCQ | |||||||
Symptoms | 171 | 2.60 | 2.60 | 0.01 | −0.14 | 0.16 | 0.92 |
Functional State | 176 | 2.03 | 2.14 | 0.11 | −0.03 | 0.25 | 0.12 |
Mental State | 174 | 2.11 | 2.20 | 0.10 | −0.09 | 0.29 | 0.32 |
Total QOL | 160 | 2.22 | 2.28 | 0.06 | −0.07 | 0.19 | 0.38 |
N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
Diabetes EQ-5D | |||||||
York A1 tariff | 301 | 0.73 | 0.72 | 0.00 | −0.01 | 0.01 | 0.60 |
VAS | 296 | 68.16 | 69.76 | 1.60 | −0.19 | 3.39 | 0.08 |
Diabetes DHP | |||||||
Psychological distress | 301 | 16.35 | 16.59 | 0.24 | −1.09 | 1.57 | 0.72 |
Barriers to activity | 282 | 22.17 | 22.39 | 0.22 | −1.22 | 1.66 | 0.76 |
Disinhibited eating | 307 | 30.16 | 30.08 | −0.09 | −1.71 | 1.54 | 0.92 |
N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
Epilepsy EQ-5D | |||||||
York A1 tariff | 95 | 0.76 | 0.76 | 0.00 | −0.02 | 0.02 | 0.89 |
VAS | 91 | 71.40 | 73.59 | 2.20 | −0.96 | 5.36 | 0.17 |
Epilepsy QOLIE | |||||||
Seizure worry | 95 | 64.49 | 65.32 | 0.82 | −3.05 | 4.69 | 0.67 |
Overall QOL | 79 | 68.26 | 68.58 | 0.32 | −2.79 | 3.42 | 0.84 |
Emotional well-being | 95 | 67.58 | 67.24 | −0.34 | −3.69 | 3.02 | 0.84 |
Energy | 98 | 54.34 | 51.99 | −2.35 | −5.18 | 0.49 | 0.10 |
Cognitive | 89 | 63.92 | 64.69 | 0.77 | −2.18 | 3.73 | 0.60 |
Medication effects | 98 | 62.59 | 61.65 | −0.94 | −5.67 | 3.80 | 0.70 |
Social function | 53 | 79.25 | 79.04 | −0.21 | −5.14 | 4.73 | 0.93 |
Total QOL | 40 | 69.92 | 70.13 | 0.22 | −2.93 | 3.36 | 0.89 |
N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
Heart failure EQ-5D | |||||||
York A1 tariff | 137 | 0.64 | 0.64 | 0.00 | −0.02 | 0.01 | 0.62 |
VAS | 145 | 62.20 | 58.67 | −3.53 | −6.69 | −0.38 | 0.03 |
Heart failure MLHFQ | |||||||
Total QOL | 80 | 36.91 | 35.10 | −1.81 | −4.46 | 0.84 | 0.18 |
Physical dimension | 125 | 18.44 | 18.02 | −0.42 | −1.62 | 0.77 | 0.48 |
Emotional dimension | 132 | 7.79 | 7.48 | −0.31 | −0.99 | 0.36 | 0.36 |
N | Baseline mean | Follow-up mean | Mean change | Lower CI (95%) | Upper CI (95%) | p | |
Stroke EQ-5D | |||||||
York A1 tariff | 93 | 0.67 | 0.67 | −0.01 | −0.03 | 0.01 | 0.45 |
VAS | 82 | 73.84 | 71.96 | −1.88 | −5.12 | 1.37 | 0.25 |
Stroke SIS | |||||||
Strength | 72 | 66.75 | 65.97 | −0.78 | −5.22 | 3.66 | 0.73 |
Hand function | 76 | 73.22 | 72.17 | −1.05 | −3.67 | 1.57 | 0.43 |
Mobility | 79 | 78.83 | 76.72 | −2.11 | −4.46 | 0.24 | 0.08 |
Memory | 91 | 81.32 | 81.04 | −0.27 | −3.23 | 2.68 | 0.85 |
ADL | 80 | 82.22 | 79.66 | −2.56 | −4.48 | −0.65 | 0.01 |
Communication | 92 | 86.88 | 85.05 | −1.82 | −4.26 | 0.61 | 0.14 |
Emotion | 77 | 72.08 | 71.90 | −0.18 | −3.56 | 3.20 | 0.92 |
Handicap | 48 | 72.20 | 72.92 | 0.72 | −3.78 | 5.21 | 0.75 |
Physical dimension | 52 | 78.08 | 76.35 | −1.72 | −3.67 | 0.23 | 0.08 |